Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 579

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 579
---
 | ​                           | ​ |    130 | ​ | ​ | ​ | ​        | ​ | 2%    | ​ | ​ | ​ | ​    | ​ |    128 | ​ | ​ | ​ | ​        | ​ | 3%    | ​ | ​ |
| Other G&A operating expenses                    | ​ | ​ | ​                           | ​ | 14,140 | ​ | ​ | ​ | ​        | ​ | 1%    | ​ | ​ | ​ | ​    | ​ | 14,060 | ​ | ​ | ​ | ​        | ​ | 15%   | ​ | ​ |
| Total G&A expense                               | ​ | ​ | ​                           | $ | 27,779 | ​ | ​ | ​ | ​        | ​ | (8)%  | ​ | ​ | ​ | ​    | $ | 30,257 | ​ | ​ | ​ | ​        | ​ | 3%    | ​ | ​ |

For the year ended December 31, 2023 compared to the year ended December 31, 2022, the decrease in stock-based compensation expense was primarily related to higher expenses recorded during the year ended December 31, 2022 for the modification of our former CEO’s equity awards, and certain performance-based restricted stock units that vested during the year ended December 31, 2022. Other Income, Net

| ​                 
 ​                 | ​ 
 ​ | ​ 
 ​ | Year Ended December 31,     
 2023                        |   |       |   |   |   |          |   |     |   | ​ | ​ | 2022 |   |       |   |   |   |          |   |      |   | ​ 
 ​ |
|:------------------|:--|:--|:----------------------------|:--|------:|:--|:--|:--|:---------|:--|:----|:--|:--|:--|:-----|:--|------:|:--|:--|:--|:---------|:--|:-----|:--|:--|
| ​                 | ​ | ​ | Dollar amounts in thousands |   |       |   |   |   |          |   |     |   |   |   |      |   |       |   |   |   |          |   |      |   | ​ |
| ​                 | ​ | ​